Disruptive anti-IgE inhibitors prevent mast cell-dependent early airway response in viable atopic lung tissue

Affiliations

• ¹ Fraunhofer Institute for Toxicology and Experimental Medicine, Member of the German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease (BREATH) research network, Hannover, Germany.
• ² Fraunhofer Institute for Toxicology and Experimental Medicine, Member of the German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease (BREATH) research network, Hannover, Germany; German Primate Center GmbH, Leibniz-Institute for Primate Research, Goettingen, Germany.
• ³ Institute for Pathology, Hannover Medical School, Hannover, Germany, Member of the German Center for Lung Research (DZL), Hannover, Germany, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH) Research Network, Hannover, Germany.
• ⁴ Institute of Pathology, Klinikum Region Hannover (KRH), Hannover, Germany.
• ⁵ German Primate Center GmbH, Leibniz-Institute for Primate Research, Goettingen, Germany.
• ⁶ Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland.
• ⁷ Fraunhofer Institute for Toxicology and Experimental Medicine, Member of the German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease (BREATH) research network, Hannover, Germany. Electronic address: katherina.sewald@item.fraunhofer.de.